$AMRN Good Morning my Friends. Here’s my quick take on yesterday’s CC & PR:
1. I believe the $20:1 r/s is a strategy to induce HF’s into investing (most require at least $5), but most importantly, I believe it’s a tactic for appealing to BP’s for M&A. The optics of a sub $1 stock for M&A is not attractive.
2. In that regard I believe negotiations are already being conducted behind closed doors. I think the most likely suitors are:
a. Novartis: Amarin has been noticed rubbing shoulders with Novartis in Spain, and Italy and I believe they would love to control the Residual CVD Market
b. Novo Nordisk needs an anti-inflammatory CV drug to complement Ozempic’s CV benefit.
c. AstraZeneca needs to protect Brilinta from generics.
3. Look for new data to drop at ACC 2025 in April, news from France? More clarity on China, and maybe the LR-eTEPA patent will be approved.
I believe the tides are shifting and patience is needed. It might be prudent to trim large positions for investments elsewhere to build dry powder for later??
GL2A.
Market Data 
Markets 
AI
